“showed a trend”

Owing to the large bouton-to-bouton variability, the absolute duration of the last 10 action potentials only showed a trend toward an increase duration ( p = 0.23 and p = 0.16 for 20 and 50 Hz, respectively; data not shown).

For instance, repeated FMT administrations showed a trend toward greater improvement in depression scores compared to single-dose interventions [SMD: -0.28; 95% CI: (-0.74, 0.18); p = 0.23], although this difference was not statistically significant.

However, the lipid profile did not worsen as indicated by the TC/HDL-c ratio, that although not significant showed a trend towards decline (-0.13, 95% CI -0.34, 0.09, p = 0.23).

High-impact exercise showed a trend towards a protective effect in non-menopausal women (OR = 0.468, 95% CI: 0.136–1.614, P = 0.230), although this was not statistically significant.

The result showed a trend toward higher rates of MPR in patients with PD-L1 CPS ≥1 (66.7% vs 37.5%; p=0.23, figure 2E ), although patient survival, such as RFS and OS, were not stratified by PD-L1 expression ( online supplemental figure 2 ), likely related to the immaturity of the data.

14 , 15 For thapsigargin-exposed iHCECs, oxotremorine treatment showed a trend for reduced ATF4 mRNA expression to 118.2 ± 43.7% ( P = 0.23) compared with untreated controls (148.3 ± 28.3%) and reduced CHOP mRNA expression to 112.3 ± 60.6% ( P = 0.024) compared with untreated controls (188.1 ± 8.0%; Fig. 7 A).

Fos showed a trend of increase with duration of SS toward the end of the light-phase in mPFC (Pearson’s correlation coefficient = 0.25, p = 0.23), indicating that the trend of Fos expression decrease with duration of sleep is specific to the VLPO-Gal neurons.

We also divided all patients by the type of first-line EGFR TKIs they received, and the second-generation TKI treatment showed a trend toward having the worst PFS ( P = 0.23; Fig. 4 C).

Analysis of the distribution of age at diagnosis (logS~age at diagnosis) of patients with REC-III variants showed a trend for a higher age at diagnosis for the subgroup with established IP variants (IP: median 15.2 (4.8–39.3) vs. no IP observed: median 8.5 (0.9–45.1), p = 0.23) ( Figure 5 ).

The results were not significantly different between the 2 groups in RCTs but showed a trend toward decreased risk in the deferred‐stenting group (OR 0.51, 95%CI 0.17‐1.53, P =0.23; Figure 2 ).

In contrast to previous literature on endometrioid endometrial cancers, SFRP4 expression was similarly distributed in all histological subtypes of ovarian cancer ( Figure 4 A ), although in plasma, patients with endometrioid ovarian cancers showed a trend towards higher SFRP4 expression (N.S. p = 0.23; Figure 4 C ).

Notably, CAPN14 mRNA expression in esophageal biopsies showed a trend of being lower in patients with familial EoE than non-familial EoE ( P = 0.23) (Supplementary Fig. 11a ).

The prevalence of γH2AX + cells only showed a trend of increase by 7 dpi at D35 (14% in control vs. 21% after HI, p = 0.23), but had returned to basal levels with even a modest reduction by 14 dpi at D42 (8% in control vs. 6% after HI, p = 0.005) ( Figures 2A,B ), perhaps reflecting enhanced DNA repair capability among the surviving population.

In the ACCI ≥ 6 group, although not statistically significant, patients receiving concurrent hRT with TMZ showed a trend toward a better OS than did those receiving Stupp (HR = 0.51, 95% CI: 0.17–1.53, p = 0.23).

The treatments showed a trend of improved blood glucose concentration at 120 min during 75 g OGTT (148.8 ± 21.1 vs. 142.9 ± 19.1 mg/dL; p = 0.23) and resulted in a significant increase of normal glucose tolerance (NGT) response in PA patients ( n = 13, from 23% to 38%) ( p = 0.0004, Chi-square test) ( Figure 7 A,B).

We also found that the convalescents that progressed with severe forms of the disease showed a trend towards an increase in the relative frequency of the NK + cells (adjusted OR: 2.32; 95% IC: 0.58–9.28; p = 0.2320) and a rise in the relative frequency (adjusted OR: 1.49; 95% IC: 0.37–6.08; p = 0.5790), and absolute frequency of CD3 + CD8+ (adjusted OR: 3.23; 95% IC: 0.95–11.0; p = 0.0610) ( Fig. 4 , Table 1 S).

Regarding other transplant outcomes, FLT3-ITD –positive patients showed a trend toward increased CIR (2-year CIR: 22.8% [95% CI, 21.8–23.9] vs. 15.2% [95% CI, 14.8–15.5], p = 0.233), as well as inferior OS (2-year OS: 70.9% [95% CI, 57.0–88.0] vs. 76.0% [95% CI, 67.3–85.8], p = 0.399); however, none of these differences reached statistical significance (Fig. 3 B and C).

Even though the p values were not statistically significant (due to the large variation between individuals), the abundance of Staphylococcus in the other three skin sites (hind paw, flank, and front paw) showed a trend towards higher abundances in cADpre dogs than in healthy dogs ( p = 0.2331, p = 0.1221, and p = 0.2889, respectively; Figure S 7 f–h).

B cell counts, which were identified by CD19 expression, showed a trend of elevation in blood samples from children with XLRS, in which the counts were 41% higher on average ( p = 0.2348, Fig. 2 b; Table 3 ).

BMI showed a trend toward correlation with troponin that did not reach statistical significance (Spearman’s ρ = 0.152, p = 0.237).

The mAb pretreatment showed a trend towards a similar level of protection versus contemporaneous controls (75%, p = 0.237), with 2 infections in 20 challenges.

The Lidocaine group showed a trend toward a more prolonged anesthetic effect, demonstrating better immediate postoperative pain proportions (lower moderate pain and higher no pain, p = 0.239), along with a significantly improved cooperation score ( p = 0.006).

Iloprost showed a trend toward reduced digital amputation risk, although heterogeneity was high (RR = 0.09; 95% CI: 0.00–5.04; p =.24; I 2 = 88%).

While our cohort of ALK-positive NSCLC patients was heterogeneous in terms of their treatment history prior to blood collection, higher ALK autoantibody levels showed a trend toward more favorable overall survival outcomes (P=0.24, Figure 4 ), although there were several early censoring events in this analysis.

They also showed a trend for higher serum levels of a-fetoprotein, which is a diagnostic marker of HCC ( p = 0.24).